NASDAQ : ORKA
Oruka Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 96.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.41B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 26.05M | 21.41M | 14.25M |
| Research & Development | 129.03M | 100.64M | 81.01M |
| Operating Expenses | 155.08M | 122.05M | 95.26M |
| Operating Income | -155.08M | -122.05M | -95.26M |
| Interest Expense | -1.60M | ||
| Interest & Investment Income | 22.18M | 16.63M | 6.40M |
| Other Non Operating Income (Expenses) | 7.00K | -12.00K | 4.36K |
| EBT Excluding Unusual Items | -132.89M | -105.43M | -90.46M |
| Other Unusual Items | -872.73K | ||
| Pretax Income | -132.89M | -105.43M | -91.34M |
| Net Income | -132.89M | -105.43M | -91.34M |
| Preferred Dividends & Other Adjustments | -23.20M | -21.12M | -20.39M |
| Net Income to Common | -109.69M | -84.31M | -70.95M |
| Shares Outstanding (Basic) | 54.19M | 45.61M | 16.79M |
| Shares Outstanding (Diluted) | 54.19M | 45.61M | 16.79M |
| EPS (Basic) | -2.02 | -1.85 | -4.23 |
| EPS (Diluted) | -2.02 | -1.85 | -4.23 |
| Free Cash Flow | -101.15M | -88.42M | -63.30M |
| Free Cash Flow Per Share | -1.87 | -1.94 | -3.77 |
| EBITDA | -154.94M | -121.97M | -95.23M |
| D&A For EBITDA | 134.00K | 83.00K | 29.45K |
| EBIT | -155.08M | -122.05M | -95.26M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 268.47M | 46.94M | 61.58M |
| Short-Term Investments | 605.09M | 290.11M | 314.07M |
| Cash & Short-Term Investments | 873.56M | 337.04M | 375.65M |
| Prepaid Expenses | 10.99M | 6.81M | 1.22M |
| Total Current Assets | 884.56M | 343.86M | 376.87M |
| Property, Plant & Equipment | 2.69M | 2.12M | 1.04M |
| Long-Term Investments | 252.02M | 142.54M | 18.07M |
| Other Long-Term Assets | 128.00K | 103.00K | 43.00K |
| Total Assets | 1.14B | 488.62M | 396.02M |
| Accounts Payable | 7.95M | 4.16M | 3.46M |
| Accrued Expenses | 14.35M | 10.60M | 9.37M |
| Current Portion of Leases | 669.00K | 619.00K | 213.00K |
| Total Current Liabilities | 22.97M | 15.37M | 13.04M |
| Long-Term Leases | 1.88M | 1.31M | 755.00K |
| Total Liabilities | 24.84M | 16.69M | 13.80M |
| Common Stock | 61.00K | 49.00K | 37.00K |
| Additional Paid-In Capital | 1.38B | 657.56M | 463.02M |
| Retained Earnings | -262.18M | -189.16M | -83.72M |
| Comprehensive Income & Other | -1.70M | 546.00K | -41.00K |
| Total Common Equity | 1.11B | 469.00M | 379.29M |
| Shareholders' Equity | 1.11B | 471.93M | 382.22M |
| Total Liabilities & Equity | 1.14B | 488.62M | 396.02M |
| Total Debt | 2.55M | 1.93M | 968.00K |
| Net Cash (Debt) | 1.12B | 477.65M | 392.75M |
| Net Cash Per Share | 20.72 | 10.47 | 23.39 |
| Filing Date Shares Outstanding | 66.21M | 49.54M | 37.44M |
| Total Common Shares Outstanding | 61.07M | 48.72M | 37.44M |
| Working Capital | 861.59M | 328.48M | 363.83M |
| Book Value Per Share | 18.20 | 9.63 | 10.13 |
| Tangible Book Value | 1.11B | 469.00M | 379.29M |
| Tangible Book Value Per Share | 18.20 | 9.63 | 10.13 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -132.89M | -105.43M | -91.34M |
| Depreciation & Amortization | 134.00K | 83.00K | 29.45K |
| Loss (Gain) From Sale of Investments | -3.10M | -5.00M | -2.45M |
| Stock-Based Compensation | 28.53M | 24.24M | 16.28M |
| Other Operating Activities | 563.00K | 458.00K | 1.74M |
| Change in Accounts Payable | 3.17M | -5.32M | 10.35M |
| Change in Other Net Operating Assets | 2.67M | 2.77M | 2.30M |
| Operating Cash Flow | -100.92M | -88.21M | -63.09M |
| Capital Expenditures | -235.00K | -209.00K | -206.18K |
| Investment in Securities | -569.62M | -96.54M | -359.93M |
| Investing Cash Flow | -569.86M | -96.75M | -360.14M |
| Total Debt Issued | 27.25M | ||
| Net Debt Issued (Repaid) | 27.25M | ||
| Issuance of Common Stock | 873.85M | 170.31M | 459.96M |
| Financing Cash Flow | 873.85M | 170.31M | 490.41M |
| Net Cash Flow | 203.07M | -14.64M | 67.17M |
| Free Cash Flow | -101.15M | -88.42M | -63.30M |
| Free Cash Flow Per Share | -1.87 | -1.94 | -3.77 |
| Levered Free Cash Flow | -65.03M | -55.83M | |
| Unlevered Free Cash Flow | -65.03M | -55.83M | |
| Change in Working Capital | 5.84M | -2.56M | 12.64M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 6.32B | 1.47B | 678.62M |
| Enterprise Value | 5.20B | 971.21M | 324.51M |
| Last Close Price | 96.87 | 30.31 | 19.39 |
| PB Ratio | 5.32 | 3.11 | 1.77 |
| P/TBV Ratio | 5.64 | 3.13 | 1.79 |
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 |
| Net Debt / Equity Ratio | -1.01 | -1.01 | -1.03 |
| Net Debt / EBITDA Ratio | 7.25 | 3.92 | 4.12 |
| Net Debt / FCF Ratio | 11.10 | 5.40 | 6.20 |
| Quick Ratio | 38.03 | 21.92 | 28.80 |
| Current Ratio | 38.51 | 22.37 | 28.89 |
| Return on Equity (ROE) | -18.23% | -24.69% | |
| Return on Assets (ROA) | -12.95% | -17.25% | |
| Return on Capital Employed (ROCE) | -13.90% | -25.80% | -24.90% |
| Earnings Yield | -2.12% | -7.19% | -13.46% |
| FCF Yield | -1.61% | -6.03% | -9.33% |
| Buyback Yield / Dilution | -49.96% | -171.69% |